Sarah, a 42-year-old teacher, used to live in fear of dinner. One wrong bite—a creamy soup, a slice of pie—could send her doubling over in pain by midnight. She has a rare condition where her body can’t break down fat. Triglycerides build up in her blood, putting her at high risk for sudden, severe pancreatitis. Hospital stays became routine. Then she joined a trial for a new drug. For the first time in years, she made it through the holidays without a single attack.
She’s not alone. Thousands live with extreme hypertriglyceridemia, often due to a rare inherited disorder called familial chylomicronaemia syndrome (FCS). Their triglyceride levels can soar past 2,000 mg/dL—normal is under 150. That puts them at constant risk for acute pancreatitis, a painful and dangerous inflammation of the pancreas. Current care means strict low-fat diets and managing symptoms. But prevention? Until now, there was no proven treatment to stop attacks before they start.
No one saw this protein as a target
For years, doctors focused on diet and general lipid-lowering drugs. But those often don’t work well for people with FCS. The real culprit? A protein in the liver called apolipoprotein C-III, or ApoC-III. It acts like a brake on the body’s ability to clear fat from the blood. Too much ApoC-III means fat-carrying particles called chylomicrons pile up. It’s like a traffic jam on a highway where no cars can exit. The longer it lasts, the higher the risk of a pancreas flare-up.
But here’s the twist: a new drug called plozasiran doesn’t just lower fat levels. It silences the gene that makes ApoC-III. Think of it like removing the brake. The body can finally clear triglycerides from the bloodstream. And when it does, the risk of pancreatitis drops.
This isn’t a supplement or a diet tweak. Plozasiran is a type of RNA therapy. It’s a small molecule injected under the skin every three months. It travels to the liver and tells cells to stop producing ApoC-III. Less protein means faster fat clearance.
The trial included 67 adults with extreme triglycerides and a history of at least one pancreatitis attack. Most had levels over 2,000 mg/dL. They were split into groups. Some got plozasiran at two different doses. Others got a placebo. All were followed for one year.
The results were clear. People on plozasiran saw their triglyceride levels drop by more than 75%. Their median level fell below 500 mg/dL—a major shift. But the real win was in hospital visits. In the placebo group, 5 out of 22 had another pancreatitis attack. In the plozasiran group, only 2 out of 45 did. That’s an 83% lower risk.
Hospital stays were shorter. Pain episodes were less severe. Some patients went a full year without a single flare-up.
But there's a catch.
This was a post hoc analysis of a larger trial. That means researchers looked back at a subgroup of patients after the main study ended. The overall trial was designed to test triglyceride levels, not just pancreatitis outcomes. Still, the drop in attacks was large enough to be statistically significant—a rare win in rare disease research.
Experts say this is the first time any treatment has shown a clear reduction in recurrent pancreatitis for this group in a controlled trial. For a condition with no approved preventive therapy, that’s meaningful progress.
What does this mean for patients today?
This doesn't mean this treatment is available yet.
Plozasiran is still under review. It’s not approved by the FDA or other health agencies. The full trial results are promising, but more data may be needed. If approved, it would likely be for people with FCS and a history of pancreatitis—those who need it most.
There are limits. The study was small. Only 67 people were analyzed. And it lasted just one year. Long-term safety and effectiveness are still unknown. The drug was well tolerated, but rare side effects could emerge in larger groups.
What happens next?
The drug’s makers are working with regulators to review the data. Larger studies may follow. If all goes well, approval could come in the next few years. For now, patients should talk to their doctors about managing triglycerides and watch for updates. For people like Sarah, a future with fewer hospital trips—and more holiday meals—might finally be in sight.